Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients
Objective: There is an increasing incidence of Helicobacter pylori eradication therapy failure secondary to antibiotic resistance. In this study, we aimed to assess the P-glycoprotein expression levels among subjects who were H. pylori-positive and received multiple courses of eradication therapy to...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/4412 |
| _version_ | 1848744508758425600 |
|---|---|
| author | Omar, Marhanis Crowe, Andrew Tay, C. Hughes, Jeff |
| author_facet | Omar, Marhanis Crowe, Andrew Tay, C. Hughes, Jeff |
| author_sort | Omar, Marhanis |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Objective: There is an increasing incidence of Helicobacter pylori eradication therapy failure secondary to antibiotic resistance. In this study, we aimed to assess the P-glycoprotein expression levels among subjects who were H. pylori-positive and received multiple courses of eradication therapy to understand factors that may associate with their non-responses. Methods: Eleven resistant subjects were recruited during their hospital visit for upper gastrointestinal endoscopies. H. pylori infection status was confirmed by rapid urease test and bacterial culture. P-glycoprotein expressions from the antral and duodenal biopsies were measured by Western blot. The data was compared with H. pylori-negative (n = 54) and H. pylori-positive-treatment naïve (n = 22) that were recruited earlier in another study. Results: The resistant group showed higher relative antral P-glycoprotein expression com-pared to the H. pylori-negative group ( p = 0.0361). Most subjects demonstrated resistance to clarithromycin (72%), metronidazole (63.6%) or both (54.5%). No significant difference was observed between the P-glycoprotein expression in H. pylori-treatment resistant and H. pylori-positive-treatment naïve groups ( p = 0.319). Conclusion: H. pylori infection induces the expression of P-glycoprotein in the antrum. This study shows a potential protective mechanism which may be exploited through the use of P-glycoprotein inducers, such as rifabutin, may be beneficial in eradication regimens. |
| first_indexed | 2025-11-14T06:02:35Z |
| format | Journal Article |
| id | curtin-20.500.11937-4412 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:02:35Z |
| publishDate | 2014 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-44122017-09-13T14:46:23Z Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients Omar, Marhanis Crowe, Andrew Tay, C. Hughes, Jeff Peptic ulcer disease Protein expression ABCB1 Gastrointestinal tract Antibiotic resistance Objective: There is an increasing incidence of Helicobacter pylori eradication therapy failure secondary to antibiotic resistance. In this study, we aimed to assess the P-glycoprotein expression levels among subjects who were H. pylori-positive and received multiple courses of eradication therapy to understand factors that may associate with their non-responses. Methods: Eleven resistant subjects were recruited during their hospital visit for upper gastrointestinal endoscopies. H. pylori infection status was confirmed by rapid urease test and bacterial culture. P-glycoprotein expressions from the antral and duodenal biopsies were measured by Western blot. The data was compared with H. pylori-negative (n = 54) and H. pylori-positive-treatment naïve (n = 22) that were recruited earlier in another study. Results: The resistant group showed higher relative antral P-glycoprotein expression com-pared to the H. pylori-negative group ( p = 0.0361). Most subjects demonstrated resistance to clarithromycin (72%), metronidazole (63.6%) or both (54.5%). No significant difference was observed between the P-glycoprotein expression in H. pylori-treatment resistant and H. pylori-positive-treatment naïve groups ( p = 0.319). Conclusion: H. pylori infection induces the expression of P-glycoprotein in the antrum. This study shows a potential protective mechanism which may be exploited through the use of P-glycoprotein inducers, such as rifabutin, may be beneficial in eradication regimens. 2014 Journal Article http://hdl.handle.net/20.500.11937/4412 10.1016/j.jab.2014.02.001 Elsevier restricted |
| spellingShingle | Peptic ulcer disease Protein expression ABCB1 Gastrointestinal tract Antibiotic resistance Omar, Marhanis Crowe, Andrew Tay, C. Hughes, Jeff Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title | Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title_full | Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title_fullStr | Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title_full_unstemmed | Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title_short | Expressions of P-glycoprotein in treatment: Resistant Helicobacter pylori patients |
| title_sort | expressions of p-glycoprotein in treatment: resistant helicobacter pylori patients |
| topic | Peptic ulcer disease Protein expression ABCB1 Gastrointestinal tract Antibiotic resistance |
| url | http://hdl.handle.net/20.500.11937/4412 |